These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 10669166)

  • 1. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source.
    Favaloro EJ
    Thromb Haemost; 2000 Jan; 83(1):127-35. PubMed ID: 10669166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems.
    Favaloro EJ; Henniker A; Facey D; Hertzberg M
    Thromb Haemost; 2000 Oct; 84(4):541-7. PubMed ID: 11057847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options.
    Favaloro EJ
    Am J Clin Pathol; 2000 Oct; 114(4):608-18. PubMed ID: 11026108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
    Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
    Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey.
    Favaloro EJ
    Semin Thromb Hemost; 2002 Apr; 28(2):191-202. PubMed ID: 11992242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel.
    Favaloro EJ; Smith J; Petinos P; Hertzberg M; Koutts J
    Thromb Haemost; 1999 Oct; 82(4):1276-82. PubMed ID: 10544913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of collagen-binding assay for von Willebrand disease].
    Zhou J; Jia YQ; Jiang H; Yang YM; Deng CQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):126-9. PubMed ID: 14981837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a collagen-binding activity assay as a screening test for type II von Willebrand disease in dogs.
    Sabino EP; Erb HN; Catalfamo JL
    Am J Vet Res; 2006 Feb; 67(2):242-9. PubMed ID: 16454628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL; Siekmann J; Schwarz HP
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD.
    Favaloro EJ; Bonar R; Meiring M; Street A; Marsden K;
    Thromb Haemost; 2007 Aug; 98(2):346-58. PubMed ID: 17721617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease.
    Favaloro EJ
    Thromb Haemost; 2010 Nov; 104(5):1009-21. PubMed ID: 20806123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
    Neugebauer BM; Goy C; Budek I; Seitz R
    Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease.
    Favaloro EJ
    Blood Rev; 1999 Dec; 13(4):185-204. PubMed ID: 10741895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification.
    Favaloro EJ; Bonar R; Marsden K
    Clin Lab Sci; 2008; 21(3):178-83. PubMed ID: 18678140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays.
    Favaloro EJ
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):553-64. PubMed ID: 21885953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use.
    Murdock PJ; Woodhams BJ; Matthews KB; Pasi KJ; Goodall AH
    Thromb Haemost; 1997 Oct; 78(4):1272-7. PubMed ID: 9364997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.